A novel immunoassay for the quantization of CYFRA 21-1 in human serum

Journal of Clinical Laboratory Analysis

Volumn 27, Issue 4, 2013, Pages 277-283

  He, An ^a   Liu, Tian Cai ^a   Dong, Zhi Ning ^a   Ren, Zhi Qi ^a   Hou, Jing Yuan ^a   Li, Ming ^a   Wu, Ying Song ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

AlphaLISA; CYFRA 21 1; Cytokeratin fragments; Homogeneous immunoassays; Singlet oxygen

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 8; MONOCLONAL ANTIBODY; NEURON SPECIFIC ENOLASE;

ADULT; AMPLIFIED LUMINESCENT PROXIMITY HOMOGENEOUS IMMUNOASSAY; ANGINA PECTORIS; ARTICLE; BIOTINYLATION; BLOOD SAMPLING; BREAST CANCER; BRONCHITIS; CHEMOLUMINESCENCE; COLON CANCER; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; EMPHYSEMA; FEMALE; HUMAN; IMMUNOASSAY; INTESTINE OBSTRUCTION; LIVER CANCER; LIVER CIRRHOSIS; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG FIBROSIS; LUNG INFECTION; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PLEURISY; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

ALPHALISA; CYFRA 21-1; CYTOKERATIN FRAGMENTS; HOMOGENEOUS IMMUNOASSAYS; SINGLET OXYGEN;

ANTIGENS, NEOPLASM; HUMANS; IMMUNOASSAY; KERATIN-19; LUMINESCENT MEASUREMENTS; LUNG NEOPLASMS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84880384306     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21597     Document Type: Article

References (34)

1. Stieber P, Dienemann H, Hasholzner U, et al. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur J Clin Chem Clin Biochem 1993;31(10):689-694.
2. Bodenmuller H, Donie F, Kaufmann M, Banauch D. The tumor markers TPA, TPS, TPACYK and CYFRA 21-1 react differently with the keratins 8, 18 and 19. Int J Biol Markers 1994;9(2):70-74.
3. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64(5):1751-1756.
4. Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: Clinical utility for detection of recurrences. Cancer 2000;89(7):1413-1417.
5. Chyczewski L, Niklinski J, Chyczewska E, Laudanski J, Furman M. Immunohistochemical analysis of tissue localization of cytokeratin 19 in lung cancer. Rocz Akad Med Bialymst 1997;42 Suppl 1:162-172.
6. Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 2010;30(7):3099-3102.
7. Edelman MJ, Hodgson L, Rosenblatt PY, et al. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol 2012;7(4):649-654.
8. Pavicevic R, Bubanovic G, Franjevic A, Stancic-Rokotov D, Samarzija M. CYFRA 21-1 in non-small cell lung cancer: Standardisation and application during diagnosis. Coll Antropol 2008;32(2):485-498.
9. Yeh JJ, Liu FY, Hsu WH, Wang JJ, Ho ST, Kao A. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection. Lung 2002;180(5):273-279.
10. Song WA, Liu X, Tian XD, et al. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: A prospective study from China. Chin Med J (Engl) 2011;124(20):3244-3248.
11. Huang WW, Tsao SM, Lai CL, Su CC, Tseng CE. Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology 2010;42(3):224-228.
12. Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 2005;128(4):2298-2303.
13. Ferrer J, Villarino MA, Encabo G, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999;86(8):1488-1495.
14. Hara A, Watanabe H. [A case of advanced gastric cancer showing high serum CYFRA21-1 level responding to chemotherapy with S-1]. Gan To Kagaku Ryoho 2008;35(13):2405-2407.
15. Miyashita T, Nishimura G, Michiwa Y, et al. [Clinical usefulness of serum CYFRA21-1 in colorectal cancer]. Gan To Kagaku Ryoho 1996;23(12):1693-1696.
16. Wu F, Fujita J, Murota M, et al. CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. Int J Oncol 2002;21(2):441-445.
17. Uenishi T, Yamazaki O, Yamamoto T, et al. Clinical significance of serum cytokeratin-19 fragment (CYFRA 21-1) in hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006;13(3):239-244.
18. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31(1):11-24.
19. Marrakchi R, Ouerhani S, Benammar S, et al. Detection of cytokeratin 19 mRNA and CYFRA 21-1 (cytokeratin 19 fragments) in blood of Tunisian women with breast cancer. Int J Biol Markers 2008;23(4):238-243.
20. Xiong Y, Peng XP, Liang LZ, Zheng M, Li JD. Clinical significance of combined examination of pretreatment serum CYFRA21-1 and SCCAg in cervical cancer patients. Ai Zheng 2009;28(1):64-67.
21. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53(1):61-66.
22. Holdenrieder S, Von Pawel J, Duell T, et al. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer. Anticancer Res 2010;30(5):1855-1862.
23. Takada M, Masuda N, Matsuura E, et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer 1995;71(1):160-165.
24. Chapman MH, Sandanayake NS, Andreola F, et al. Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer. J Clin Exp Hepatol 2011;1(1):6-12.
25. Kuropkat C, Werner JA. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol 2003;117(12):1007-1008; author reply 1008-1009.
26. Alkotyfan K, Wiegand S, Muller HH, Windfuhr JP, Werner JA, Sesterhenn AM. Cyfra 21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharynx. Anticancer Res 2010;30(6):2291-2296.
27. Shan G, Huang W, Gee SJ, Buchholz BA, Vogel JS, Hammock BD. Isotope-labeled immunoassays without radiation waste. Proc Natl Acad Sci USA 2000;97(6):2445-2449.
28. Ullman EF, Kirakossian H, Singh S, et al. Luminescent oxygen channeling immunoassay: Measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci U S A 1994;91(12):5426-5430.
29. Ullman EF, Kirakossian H, Switchenko AC, et al. Luminescent oxygen channeling assay (LOCI): Sensitive, broadly applicable homogeneous immunoassay method. Clin Chem 1996;42(9):1518-1526.
30. Glick MR, Ryder KW, Jackson SA. Graphical comparisons of interferences in clinical chemistry instrumentation. Clin Chem 1986;32(3):470-475.
31. Bielefeld-Sevigny M. AlphaLISA immunoassay platform- the "no-wash" high-throughput alternative to ELISA. Assay Drug Dev Technol 2009;7(1):90-92.
32. Poulsen F, Jensen KB. A luminescent oxygen channeling immunoassay for the determination of insulin in human plasma. J Biomol Screen 2007;12(2):240-247.
33. McGiven JA, Sawyer J, Perrett LL, et al. A new homogeneous assay for high throughput serological diagnosis of brucellosis in ruminants. J Immunol Methods 2008;337(1):7-15.
34. Szekeres PG, Leong K, Day TA, Kingston AE, Karran EH. Development of homogeneous 384-well high-throughput screening assays for Abeta1-40 and Abeta1-42 using AlphaScreen technology. J Biomol Screen 2008;13(2):101-111.